DARK SECRETS: 2 - The Real Truth

Charles River Laboratories underperformed the broader market over the past year, and Wall Street analysts remain cautious about the stock’s prospects.

Charles River Laboratories is expected to announce its third-quarter results next month, and analysts predict a double-digit decline in the company’s bottom-line figure.

The Knights prop had no interest in rugby league five years ago.

The FDA issued a Complete Response Letter regarding the marketing application for Acer Therapeutics Inc (NASDAQ:ACER) and its collaboration partner, Relief Therapeutics Holding SA's (OTC:RLFTF) ACER-001 (sodium phenylbutyrate), for urea cycle disorders (UCDs). The CRL states: "[The FDA's] field investigator could not complete inspection of [Acer's third-party contract packaging manufacturer] because the facility was not ready…

The persistent macroeconomic and geopolitical headwinds continue to keep the stock market under immense pressure. Amid the uncertainties surrounding the stock market, it could be wise to avoid shares of Charles River Laboratories International (CRL), Credit Suisse Group AG (CS), and The Scotts Miracle-Gro (SMG) as these hard-hit companies have…

The shares of Charles River Laboratories (CRL) have plunged in price despite the company’s solid results. So, can they rebound by the company leveraging its broad portfolio of products and services? Read on. Let’s find out.

The FDA has issued a complete response letter (CRL) to Junshi Biosciences Co Ltd and Coherus BioSciences Inc's (NASDAQ:CHRS) toripalimab application for advanced recurrent or metastatic nasopharyngeal carcinoma (NPC). NPC is a rare tumor of the head and neck which originates in the nasopharynx, located behind the nose and above the back of the throat. The…

The FDA has issued a Complete Response Letter (CRL) to Axsome Therapeutics Inc's (NASDAQ:AXSM) AXS-07 for the acute treatment of migraine.  The CRL did not identify or raise any concerns about the clinical efficacy or safety data in the NDA, and the FDA did not request any new clinical trials to support the approval…

Charles River Laboratories International Inc (NYSE: CRL) has acquired Explora BioLabs Holdings Inc, a provider of contract vivarium research services,